title: Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix.
abstract: OBJECTIVE
  There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined the effectiveness and safety of paclitaxel/carboplatin (TC) and docetaxel/carboplatin (DC).
  
  
  METHODS
  Stage Ib2 to IIb disease was present in 23 patients scheduled for radical hysterectomy. We administered 1-3 courses of either the TC or the DC regimen. Anti-tumor effects were found superior by Response Evaluation Criteria in Solid Tumors. Safety was assessed with National Cancer Institute Common Terminology Criteria for Adverse Events.
  
  
  RESULTS
  Median age was 50 years (range 32-63 years), with stage Ib2 in 6 cases (26.1%) and IIb in 17 cases (73.9%). Complete response was achieved in 5 cases (21.7%), partial response in 13 (56.5%), stable disease in 5 (21.7%); the response rate was 78.3%, and surgery completion rate was 78.3%. Leukopenia or neutropenia ≥grade 3 was seen in 12 (52.2%) and 21 (91.3%) cases, respectively, with grade 3 febrile neutropenia in 2 cases (8.7%) and no anemia or thrombocytopenia ≥grade 3. Median progression-free survival was 26 months (95% Cl, 13.5-38.5 months); median overall survival was 35 months (95% Cl, 20.9-49.1 months).
  
  
  CONCLUSIONS
  NAC for non-squamous cell cervical carcinoma showed potent anti-tumor effects and manageable adverse events.
authors.affiliation: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka 020-8505, Japan. tshoji@iwate-med.ac.jp
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Shoji
authors.forename: Eriko
authors.initials: E
authors.lastname: Takatori
authors.forename: Tatsunori
authors.initials: T
authors.lastname: Saito
authors.forename: Hideo
authors.initials: H
authors.lastname: Omi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kagabu
authors.forename: Fumiharu
authors.initials: F
authors.lastname: Miura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takeuchi
authors.forename: Toru
authors.initials: T
authors.lastname: Sugiyama
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010865:Pilot Projects; D011182:Postoperative Care; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor